PCI – 7th June 2024
Temax_Krautz
Owen Mumford 12 January 2022, 17:40

Current Edition

Nasal & Pulmonary Drug Development
Cormica Banner Ad – 24.02.2025
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
Biosynth: Fri 4 October 2024, 10:42

How Efficient Logistics Can Change the Lives of Rare Disease Patients

Dr. Danial Arkwell, Head of Global Key Accounts, Pharma at Envirotainer highlights the vital role of efficient logistics in mitigating risk and finding the right solutions to get orphan drugs to patients in desperate need.

There are approximately eight thousand rare diseases in the world and many of these are chronic, life-threatening conditions. To fight these elusive illnesses, the medical community focuses on developing specialised medications known as orphan drugs. Originating from the United States Orphan Drug Act (ODA) in 1983, the term “Orphan Drug” reflects the lack of attention and investment necessary for their development.

The diseases targeted by orphan drugs often have low prevalence rates, making them economically unattractive to develop treatments for, due to the limited potential market. The result is that many of these diseases are being historically neglected as a result of the perceived low profitability.

The Orphan Drug Act and similar legislation aim to progress the development of drugs for rare diseases by offering various incentives to drug manufacturers. This includes tax credits for clinical research costs, seven years of market exclusivity upon approval, and assistance with clinical trials, design and funding.

Despite government support, orphan drugs have been priced significantly higher than non-orphan drugs, owing to the inherent complexities and high costs of production. The significant upfront investment required to bring these much-needed treatments to market not only slows down their development but also contributes to incredibly high prices for patients, potentially putting them out of reach for many.

Yet, there are other barriers to patients receiving life-saving treatments. One that’s frequently overlooked is the complexity of transporting these highly sensitive drugs from the lab to the end patient. If manufacturers cannot ensure safe, cost-effective delivery, then access to these rare treatments will remain out of reach for many patients. Efficient logistics must take centre stage.

Stoelzle Skyscraper: 27th November 2024
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
LBBOHLE, Thu 20 April 2023, 17:23
Nipro 14 March 2024, 11:35